BioCentury
ARTICLE | Clinical News

VLA15-101: Ph I started

December 13, 2016 10:11 PM UTC

Valneva began a single-blind, dose-escalation, international Phase I trial to evaluate VLA15-101 in about 180 healthy volunteers....

BCIQ Company Profiles

Valneva SE